FDA clears AtCor blood pressure tool in US
21 November, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has received FDA approval to market SphygmoCor XCEL, its upgraded cardiovascular diagnostics tool, in the US.
Comment: Finding an alliance partner that will maximise the value of your assets
21 November, 2012 by Staff WritersMarcus Bain, Managing Director of Wescadia Group gives a checklist for biotechnology companies of what to look for in a potential industry partner.
Beat jetlag and sleep problems with new Australian invention
21 November, 2012 by Tim DeanA new invention from Flinders University scientists can help reset the body clock, beat jetlag and allows shift workers to remain more alert and get more sleep.
Sirtex up on news of planned $4.5m manufacturing plant in Germany
20 November, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) will invest $4.5m to build a manufacturing plant in Germany for its SIR-Spheres liver cancer treatments.
Mesoblast gets go-ahead from FDA to manufacture stem cells
20 November, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) and the US FDA have reached an agreement covering the company's manufacturing process for adult stem cells to be used in phase III trials.
Food standards body calls for comment on cost recovery
20 November, 2012 by AusBiotechFood Standards Australia New Zealand (FSANZ) invites comments on consultation papers it has released on proposed cost recovery arrangements for health claims applications.
Mesoblast reaffirms Teva partnership following share slump
19 November, 2012 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has reassured shareholders of the strength of its partnership with Teva Pharmaceutical Industries after rumours circulated that Teva may exit the stem cell collaboration.
LCT wins ethics nod for NZ Ntcell trial
16 November, 2012 by Dylan Bushell-EmblingLiving Cell Technologies (ASX:LCT) has secured ethics approval for the first in-human trial of its Ntcell treatment in patients with Parkinson's disease.
Australian Life Scientists acquired by specialist laboratory publisher
15 November, 2012 by Staff WritersAustralian Life Scientist magazine, and its sister website www.lifescientist.com.au, have been acquired by Westwick-Farrow Media (WFM), and will join its stable of B2B magazines and websites, including What’s New in Lab & Life Sciences.
AmpliPhi and SPS complete merger
15 November, 2012 by Dylan Bushell-EmblingAustralia's Special Phage Services is now part of US-based AmpliPhi, following the closure of a merger between the two bacteriophage companies.
New project to support life sciences boards and directors
15 November, 2012 by AusBiotechAusBiotech, with support from the Victorian Government, has begun a project to support board and directors’ development and promote best practice reporting and governance.
Funding difficulties see Avexa turn to mining
14 November, 2012 by Dylan Bushell-EmblingAvexa (ASX:AVX) is committing most of its cash to an investment in a US coal mine to generate cash for development of its clinical programs including HIV drug ATC.
Encouraging trial results for Prima’s ovarian cancer treatment
14 November, 2012 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has published a second set of encouraging early data from a phase II trial of CVac in ovarian cancer
Viralytics R&D Tax rebate higher than expected
13 November, 2012 by Dylan Bushell-EmblingViralytics (ASX:VLA) has received nearly $1.5m as an R&D Tax Incentive rebate, and will plough the funds back into its oncolytic virus clinical development.
Vic Gov launches Technology Voucher Program
13 November, 2012 by AusBiotechGrowing on the success of the “Small Technologies Industry Uptake Program” the Victorian Government has launched a new “Technology Voucher Program” (TVP).
